# Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma

> **NCT04184518** · PHASE2 · WITHDRAWN · sponsor: **Grupo Español Multidisciplinar de Melanoma**

## Conditions studied

- Uveal Melanoma
- Metastatic Cancer

## Interventions

- **DRUG:** Cediranib Maleate
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04184518
- **Lead sponsor:** Grupo Español Multidisciplinar de Melanoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The Cediranib producer laboratory decided to stop the development of this product.
- **Last updated:** 2020-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184518, "Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04184518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*